Psoriasis as risk factor for non-ischemic dilated cardiomyopathy: a population-based cross-sectional study.
Autoimmune disease
Cardiovascular disease
Non-ischemic dilated cardiomyopathy
Psoriasis
Psoriatic arthritis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
31 03 2021
31 03 2021
Historique:
received:
06
02
2021
accepted:
30
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
6
10
2021
Statut:
epublish
Résumé
Psoriasis is a chronic inflammatory skin condition commonly associated with psoriatic arthritis, malignancy, diabetes, inflammatory bowel disease, and cardiovascular disease. Several reports and studies have reported an association between psoriasis and non-ischemic dilated cardiomyopathy (NIDCM). We aim to study the relationship between psoriasis and non-ischemic dilated cardiomyopathy in a large population-based study. We utilized the Healthcare Cost and Utilization Project National Inpatient Sample 2017 database, which represents a 20% sample of all payer hospitalizations in the United States. We investigated hospitalizations for patients aged 18 years old or older with diagnoses of any type of psoriasis and non-ischemic dilated cardiomyopathy. Psoriasis, cardiomyopathy, and other comorbidities were identified through their international classification of diseases, 10th revision codes recorded in the discharge record for each hospitalization. Of a total of 6,084,184 all-cause admissions, 0.5% were admissions for patients with psoriasis (n = 32,807). Of the patients with and without psoriasis who had non-ischemic dilated cardiomyopathy, after adjusting for age, sex, race, diabetes mellitus, hypertension, alcohol abuse, cocaine abuse, arrhythmias, and obesity in a multivariate analysis, the presence of psoriasis was not significantly associated with non-ischemic dilated cardiomyopathy. Psoriasis is a chronic autoimmune disorder which carries a higher cardiovascular events and more prevalent traditional atherosclerotic risk factors in comparison to the general population. However, association with non-ischemic cardiomyopathy or NIDCM in particular has not been studied sufficiently. Our study, being one of the first larger studies to assess this correlation, indicated no relationship between psoriasis and non-ischemic dilated cardiomyopathy.
Sections du résumé
BACKGROUND
Psoriasis is a chronic inflammatory skin condition commonly associated with psoriatic arthritis, malignancy, diabetes, inflammatory bowel disease, and cardiovascular disease. Several reports and studies have reported an association between psoriasis and non-ischemic dilated cardiomyopathy (NIDCM). We aim to study the relationship between psoriasis and non-ischemic dilated cardiomyopathy in a large population-based study.
METHODS
We utilized the Healthcare Cost and Utilization Project National Inpatient Sample 2017 database, which represents a 20% sample of all payer hospitalizations in the United States. We investigated hospitalizations for patients aged 18 years old or older with diagnoses of any type of psoriasis and non-ischemic dilated cardiomyopathy. Psoriasis, cardiomyopathy, and other comorbidities were identified through their international classification of diseases, 10th revision codes recorded in the discharge record for each hospitalization.
RESULTS
Of a total of 6,084,184 all-cause admissions, 0.5% were admissions for patients with psoriasis (n = 32,807). Of the patients with and without psoriasis who had non-ischemic dilated cardiomyopathy, after adjusting for age, sex, race, diabetes mellitus, hypertension, alcohol abuse, cocaine abuse, arrhythmias, and obesity in a multivariate analysis, the presence of psoriasis was not significantly associated with non-ischemic dilated cardiomyopathy.
CONCLUSION
Psoriasis is a chronic autoimmune disorder which carries a higher cardiovascular events and more prevalent traditional atherosclerotic risk factors in comparison to the general population. However, association with non-ischemic cardiomyopathy or NIDCM in particular has not been studied sufficiently. Our study, being one of the first larger studies to assess this correlation, indicated no relationship between psoriasis and non-ischemic dilated cardiomyopathy.
Identifiants
pubmed: 33789595
doi: 10.1186/s12872-021-01972-0
pii: 10.1186/s12872-021-01972-0
pmc: PMC8015089
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161Commentaires et corrections
Type : ErratumIn
Références
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. https://doi.org/10.1111/jdv.13854 .
doi: 10.1111/jdv.13854
pubmed: 27573025
pmcid: 27573025
Benhadou F, Mintoff D, Schnebert B, Thio HB. Psoriasis and microbiota: a systematic review. Diseases. 2018;6(2):47. https://doi.org/10.3390/diseases6020047 .
doi: 10.3390/diseases6020047
pmcid: 6023392
Taylor SL, Petrie M, O’Rourke KS, Feldman SR. Rheumatologists’ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients’ joint symptoms. J Dermatol Treat. 2009;20(6):350–3. https://doi.org/10.3109/09546630902817887 .
doi: 10.3109/09546630902817887
pubmed: 19878036
Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, Feldman SR. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat. 2005;16(5–6):319–23. https://doi.org/10.1080/09546630500335977 .
doi: 10.1080/09546630500335977
pubmed: 16428152
Kimhi O, Caspi D, Bornstein N, Maharshak N, Gur A, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203–9. https://doi.org/10.1016/j.semarthrit.2006.09.001 .
doi: 10.1016/j.semarthrit.2006.09.001
pubmed: 17067658
Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, Fraeman K, Bala M. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217:27–37. https://doi.org/10.1159/000121333 .
doi: 10.1159/000121333
Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131–5. https://doi.org/10.1136/ard.2008.094839 .
doi: 10.1136/ard.2008.094839
pubmed: 18697777
Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord–Trøndelag health study. Ann Rheum Dis. 2016;75(5):819–24. https://doi.org/10.1136/annrheumdis-2014-206824 .
doi: 10.1136/annrheumdis-2014-206824
pubmed: 25814652
Khraishi M, Aslanov R, Rampakakis E, Pollock C, Sampalis JS. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol. 2014;33(10):1495–500. https://doi.org/10.1007/s10067-014-2743-7 .
doi: 10.1007/s10067-014-2743-7
pubmed: 25034080
Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32. https://doi.org/10.1136/annrheumdis-2014-205675 .
doi: 10.1136/annrheumdis-2014-205675
pubmed: 25351522
Kristensen SL, McInnes IB, Sattar N. Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Ann Rheum Dis. 2015;74:321–2. https://doi.org/10.1136/annrheumdis-2014-206617 .
doi: 10.1136/annrheumdis-2014-206617
pubmed: 25429028
Yim KM, Armstrong AW. Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. Rheumatol Int. 2017;37(1):97–105. https://doi.org/10.1007/s00296-016-3487-2 .
doi: 10.1007/s00296-016-3487-2
pubmed: 27221457
Kibari A, Cohen AD, Gazitt T, et al. Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study. Clin Rheumatol. 2019;38:2069–75. https://doi.org/10.1007/s10067-019-04528-y .
doi: 10.1007/s10067-019-04528-y
pubmed: 30937638
Baeta I, Bittencourt F, Gontijo B, et al. Comorbidities and cardiovascular risk factors in patients with psoriasis. An Bras Dermatol. 2014;89(5):735–44. https://doi.org/10.1590/abd1806-4841.20142874 .
doi: 10.1590/abd1806-4841.20142874
pubmed: 25184912
pmcid: 4155951
Eliakim-Raz N, Shuvy M, Lotan C, Planer D. Psoriasis and dilated cardiomyopathy: coincidence or associated diseases? Cardiology. 2008;111(3):202–6. https://doi.org/10.1159/000121605 .
doi: 10.1159/000121605
pubmed: 18434726
Abdelaoui B, Benlafkih O, Ztati M, Karimi S, et al. The diagnosis of dilated cardiomyopathy during extended psoriasis: case report. Int J Adv Res. 2020;8(01):596–600. https://doi.org/10.21474/IJAR01/10335 .
doi: 10.21474/IJAR01/10335
Pietrzak A, Brzozowska A, Lotti T, Mosiewicz J, Wysokiński A, et al. Psoriasis and cardiovascular. Dermatol Ther. 2013;26:489–92. https://doi.org/10.1111/dth.12021 .
doi: 10.1111/dth.12021
pubmed: 24552414
Fukuhara K, Urano Y, Akaike M, Ahsan K, Arase S. Psoriatic arthritis associated with dilated cardiomyopathy and Takayasu’s arteritis. Br J Dermatol. 1998;138:329–33. https://doi.org/10.1046/j.1365-2133.1998.02085.x .
doi: 10.1046/j.1365-2133.1998.02085.x
pubmed: 9602885
Zhao C-T, Yeung C-K, Siu C-W, Tam S, Chan J, Chen Y, Chan H-H, Tse H-F, Yiu K-H. Relationship between parathyroid hormone and subclinical myocardial dysfunction in patients with severe psoriasis. J Eur Acad Dermatol Venereol. 2014;28:461–8. https://doi.org/10.1111/jdv.12123 .
doi: 10.1111/jdv.12123
pubmed: 23489223
Milaniuk S, Pietrzak A, Mosiewicz B, Mosiewicz J, Reich K. Influence of psoriasis on circulatory system function assessed in echocardiography. Arch Dermtol Res. 2015;307(10):855–61. https://doi.org/10.1007/s00403-015-1586-7 .
doi: 10.1007/s00403-015-1586-7
Biyik I, Narin A, Bozok M, Ergene O. Echocardiographic and clinical abnormalities in patients with psoriasis. J Int Med Res. 2006;34(6):632–9. https://doi.org/10.1177/147323000603400608 .
doi: 10.1177/147323000603400608
pubmed: 17294995
Hashim T, Ahmad A, Chaudry A, Khouzam R. Psoriasis and cardiomyopathy: a review of the literature. South Med J. 2017;110(2):97–100. https://doi.org/10.14423/SMJ.0000000000000603 .
doi: 10.14423/SMJ.0000000000000603
pubmed: 28158878
Ryabkova VA, Shubik YV, Erman MV, Churilov LP, Kanduc D, Shoenfeld Y. Lethal immunoglobulins: autoantibodies and sudden cardiac death. Autoimmun Rev. 2019;18(4):415–25. https://doi.org/10.1016/j.autrev.2018.12.005 .
doi: 10.1016/j.autrev.2018.12.005
pubmed: 30772491
Prussick L, Jimenez E, Nussbaum D, Prussick R. Psoriasis and psychological comorbidities. J Psoriasis Psoriatic Arthritis. 2016;1:80–5. https://doi.org/10.1177/247553031600100206 .
doi: 10.1177/247553031600100206
Svanström C, Lonne-Rahm SB, Nordlind K. Psoriasis and alcohol. Psoriasis. 2019;9:75–9. https://doi.org/10.2147/PTT.S164104 .
doi: 10.2147/PTT.S164104
pubmed: 31687362
pmcid: 6709030
Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol. 2019;60(2):91–8. https://doi.org/10.1111/ajd.12895 .
doi: 10.1111/ajd.12895
pubmed: 30079566